253 related articles for article (PubMed ID: 26018735)
1. Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus.
Giunco S; Celeghin A; Gianesin K; Dolcetti R; Indraccolo S; De Rossi A
Cell Death Dis; 2015 May; 6(5):e1774. PubMed ID: 26018735
[TBL] [Abstract][Full Text] [Related]
2. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
[TBL] [Abstract][Full Text] [Related]
3. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.
Terrin L; Dolcetti R; Corradini I; Indraccolo S; Dal Col J; Bertorelle R; Bonaldi L; Esposito G; De Rossi A
Int J Cancer; 2007 Aug; 121(3):576-87. PubMed ID: 17417773
[TBL] [Abstract][Full Text] [Related]
4. Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications.
Giunco S; Petrara MR; Zangrossi M; Celeghin A; De Rossi A
Infect Agent Cancer; 2018; 13():14. PubMed ID: 29643934
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
[TBL] [Abstract][Full Text] [Related]
6. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
7. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
8. Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.
Celeghin A; Giunco S; Freguja R; Zangrossi M; Nalio S; Dolcetti R; De Rossi A
Cell Death Dis; 2016 Dec; 7(12):e2562. PubMed ID: 28032863
[TBL] [Abstract][Full Text] [Related]
9. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
Robinson AR; Kwek SS; Kenney SC
PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
[TBL] [Abstract][Full Text] [Related]
10. EBNA2 and activated Notch induce expression of BATF.
Johansen LM; Deppmann CD; Erickson KD; Coffin WF; Thornton TM; Humphrey SE; Martin JM; Taparowsky EJ
J Virol; 2003 May; 77(10):6029-40. PubMed ID: 12719594
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase.
Liu X; Cohen JI
J Virol; 2016 Jan; 90(2):1129-38. PubMed ID: 26559845
[TBL] [Abstract][Full Text] [Related]
12. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.
Lin KM; Lin SJ; Lin JH; Lin PY; Teng PL; Wu HE; Yeh TH; Wang YP; Chen MR; Tsai CH
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776277
[TBL] [Abstract][Full Text] [Related]
14. EBV lytic infection enhances transformation of B-lymphocytes infected with EBV in the presence of T-lymphocytes.
Katsumura KR; Maruo S; Takada K
J Med Virol; 2012 Mar; 84(3):504-10. PubMed ID: 22246839
[TBL] [Abstract][Full Text] [Related]
15. Shutoff of BZLF1 gene expression is necessary for immortalization of primary B cells by Epstein-Barr virus.
Yu X; McCarthy PJ; Wang Z; Gorlen DA; Mertz JE
J Virol; 2012 Aug; 86(15):8086-96. PubMed ID: 22623769
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.
Larcher C; Bernhard D; Schaadt E; Adler B; Ausserlechner MJ; Mitterer M; Huemer HP
Haematologica; 2003 Dec; 88(12):1324-35. PubMed ID: 14687985
[TBL] [Abstract][Full Text] [Related]
17. Nascent Transcriptomics Reveal Cellular Prolytic Factors Upregulated Upstream of the Latent-to-Lytic Switch Protein of Epstein-Barr Virus.
Frey TR; Brathwaite J; Li X; Burgula S; Akinyemi IA; Agarwal S; Burton EM; Ljungman M; McIntosh MT; Bhaduri-McIntosh S
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941784
[TBL] [Abstract][Full Text] [Related]
18. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
19. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Ye J; Gradoville L; Daigle D; Miller G
J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus MicroRNA miR-BART20-5p Suppresses Lytic Induction by Inhibiting BAD-Mediated caspase-3-Dependent Apoptosis.
Kim H; Choi H; Lee SK
J Virol; 2016 Feb; 90(3):1359-68. PubMed ID: 26581978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
